Bio-Tech KBLB Moving on News
Sept 24, 2010 Boca Raton, FL– TheStockwizards.net analyzes up-to-the-minute OTC-OTCBB, NYSE, and NASDAQ Small,Micro Cap Penny Stocks like OTCBB KBLB that are active gainers on news. TSW looks for penny stocks like OTCBB KBLB that have active volume & strong momentum, percentage gainers for the mid-morning session The best penny stocks included are:
Get the Latest Trends and Trading Tips from Veteran Penny Stocks Traders. Tour The TSW Website learn how to take home huge profits trading penny stocks like OTCBB KBLB.
Sign Up For Our Red Hot OTC Penny Stock Newsletter put out each weekend as we highlight some of the biggest moving OTCBB Penny Stocks, Small Cap & Micro Cap Stocks like OTCBB KBLB before they start breaking out. The most up-to-date weekend Penny Stocks Newsletter around. For more information on how to find stocks like kblb , go to Traders Corner.
(OTCBB: KBLB — Kraig Biocraft Laboratories, Inc.)
CURRENT NEWS!!
University of Notre Dame and KBLB Kraig Biocraft Laboratories to Hold Joint Press Conference
ANSING, MI, Sep 24, 2010 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to announce that the University of Notre Dame and KBKB Kraig Biocraft Laboratories will hold a joint press conference Wednesday, September 29, 2010 on the Notre Dame campus to describe a new research breakthrough and its possible biomedical and commercial applications.
The press conference will take place in the University of Notre Dame’s Jordan Hall of Science at 11:00 A.M. Due to space limitations, media only please. For invitations and further details the media is invited to contact Ben Hansel (720) 288-8495 begin_of_the_skype_highlighting (720) 288-8495 end_of_the_skype_highlighting.
For more information on KBLB Kraig Biocraft Laboratories please visit the Company’s web site: http://www.KraigLabs.com
(OTCBB: GETA — GETA — Genta Incorporated)
Current News !!
BERKELEY HEIGHTS, N.J., Sep 24, 2010 (BUSINESS WIRE) — Genta Incorporated (OTCBB: GETA.OB) today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.
The new study will examine the efficacy and safety of tesetaxel in patients with advanced bladder cancer who have developed progressive disease after treatment with a single 1st-line regimen. The 1st-line regimen is expected to be a combination of cisplatin plus gemcitabine (Gemzar(R); Eli Lilly, Inc.). The primary endpoint of this study is overall response rate. Secondary endpoints include durable response, disease control, progression-free survival, and safety. The dose for the new trial was determined from Genta’s ongoing studies in patients with advanced gastric cancer and advanced melanoma.
Patients who progress on 1st-line treatment for invasive bladder cancer have a poor prognosis, and toxicity is an important issue in clinical care. Compared with standard taxanes, clinical and preclinical data show that tesetaxel:
- Eliminates serious (occasional fatal) hypersensitivity reactions
- Eliminates requirements for premedication (e.g., steroids, antihistamines, etc.)
- Reduces damage to peripheral nerves
- Is not cross-resistant with standard taxanes
- Offers flexible and convenient dosing for patients
“Standard taxanes are active in bladder cancer, but as yet none has received regulatory approval”, said Dr. Raymond P. Warrell, Jr., Genta’s Chairman and Chief Executive Officer. “Recently, two large companies terminated their programs with potentially competitive agents in this indication. Thus, an important unmet need has opened for a highly active agent that may reduce side effects. Having observed preliminary activity in Phase 1, we wish to swiftly clarify the potential activity of tesetaxel in this disease that, if confirmed, could lead to registration-directed clinical trials.”
About Bladder Cancer
According to the American Cancer Society, approximately 314,000 new cases of bladder cancer are diagnosed each year, which annually results in the death of 124,000 individuals. In the U.S., annual deaths from bladder cancer are approximately one-half the number of deaths due to prostate cancer.
About Tesetaxel
Taxanes (including paclitaxel and docetaxel) are the most widely used chemotherapy drug class in cancer medicine.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer.
(OTC: HEME — Healthmed Services Ltd.)
Current News !!
Alpha Software Testing Successfully Finished for Healthmed Services’ Virtual Vantage Software
SUNNYVALE, Calif., Sept 23, 2010 — Healthmed Services, Ltd. (OTC QB: HEME), an innovative software and application development company, is excited to announce the successful completion of the Alpha phase of Virtual Vantage.
Virtual Vantage is a remote access software created for the healthcare industry and professionals allowing remote and stationary access from handheld devices, such as the iPad, to servers and both stationary PC and Apple computers in all healthcare facilities such as hospitals, doctor offices, clinics and pre and post patient care facilities.
Director John Popovic, committed to developing this software since coming onboard earlier this year, has now achieved this goal. The overall acceptance and growing success of the iPad in the healthcare industry supports the Company’s objective to increase convenience and efficiency through the use of technology that is now being required for today’s healthcare professionals.
The Company anticipates Virtual Vantage will be available for additional beta testing via download in early October 2010.
For more information on the Company and its products, you may visit the Company’s website at www.healthmedltd.com.
About TheStockWizards.net
The Stock Wizards is a Premiere Penny Stocks Financial Portal & Investor Relations Firm that brings a wealth of trading resources to Small Cap Penny Stocks Investors. We analyze daily market activity on stocks like grno and provide our members with hot stocks like grno to watch every day. We follow certain chart patterns and bring you penny stock break out alerts, volume spikes, breaking news, hot stocks to watch like grno, upward trends, mergers and more…
Sign up for text message trade alerts and get hot picks like KBLB sent to your cell phone.
KBLB
